home / stock / gild / gild articles

GILD Articles, Gilead Sciences Inc.

Stock Information
Company Name: Gilead Sciences Inc.
Stock Symbol: GILD
Market: NASDAQ
Website: gilead.com
Menu
GILD GILD Quote GILD Short GILD News GILD Articles GILD Message Board
Get GILD Alerts

News, Short Squeeze, Breakout and More Instantly...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields | Benzinga

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks...
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio? | Benzinga

These large-cap stocks were the best performers in the last week. Are they in your portfolio? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares incr...

Gilead Up as Twice-Yearly HIV Shot Prevents Infection | Benzinga

Gilead Sciences, Inc. (NASDAQ: GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a p...

Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments | Benzinga

Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...
Why Gilead Sciences Stock Is Trading Higher Friday | Benzinga

Gilead Sciences, Inc. (NASDAQ:GILD) stock is moving higher Friday on continued strength following the company’s Phase 3 HIV data. What To Kno...

Why Is Gilead Sciences Stock Trading Higher On Thursday? | Benzinga

Thursday, Gilead Sciences Inc (NASDAQ:GILD) shared topline results from an interim analysis of its Phase 3 PURPOSE 1 trial indicating its twice-ye...

KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday | Benzinga

U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Thursday. Shares of KB Home (NYSE:KBH) rose during Thursday's se...
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects | Benzinga

Magrolimab was the centerpiece of Gilead Sciences Inc's (NASDAQ:GILD) $4.9 billion buyout of Forty Seven Inc in March 2020. Magrolimab is a mo...

National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection | Benzinga

U.S. National Institutes of Health has launched two clinical trials to examine a novel long-acting form of HIV pre-exposure prophylaxis (PrEP) in c...

After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies | Benzinga

On Saturday, Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences Inc (NYSE:RCUS) released longer-term efficacy and safety results fro...
Next 10